Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.57 |
| ▸ | TSHR | P16473 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.46 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.43 |
| ▸ | FOS | P01100 | 1/20 | 0.43 |
| ▸ | JUN | P05412 | 1/20 | 0.43 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.43 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2967940 | 0.86 | TRIM24 (0.55) | KDM4ETSHRLMNASMN1; SMN2TRIM24 | |
| SCHEMBL8048490 | 0.85 | TRIM24 (0.47) | KDM4ETSHRLMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL14846857 | 0.85 | SCN4A (0.46) | KDM4ETSHRSMN1; SMN2TRIM24NR1H4 | |
| SCHEMBL12094272 | 0.85 | SCN4A (0.46) | KDM4ETSHRSMN1; SMN2TRIM24NR1H4 | |
| SCHEMBL9122805 | 0.85 | LMNA (0.61) | KDM4ETSHRLMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL7263660 | 0.85 | TRIM24 (0.43) | KDM4ETSHRLMNATRIM24NR1H4 | |
| SCHEMBL9122821 | 0.85 | KDM4E (0.54) | KDM4ETSHRLMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL19191664 | 0.85 | SCN4A (0.46) | KDM4ETSHRSMN1; SMN2TRIM24NR1H4 | |
| SCHEMBL12868099 | 0.85 | KDM4E (0.54) | KDM4ETSHRLMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL9327375 | 0.85 | TSHR (0.54) | KDM4ETSHRLMNAALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239828-A1 | MANNOSE 6-PHOSPHATE OR ASGPR RECEPTOR BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS | AVILAR THERAPEUTICS, INC. (US) | 2024-07-18 | — | — | US | disclosed |
| US-20230233560-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-07-27 | — | — | US | disclosed |
| US-20230233560-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-07-27 | — | — | US | disclosed |
| US-11701370-B2 | Phosphonium ion channel blockers and methods for use | Nocion Therapeutics, Inc. (US) | 2023-07-18 | — | — | US | disclosed |
| US-11701370-B2 | Phosphonium ion channel blockers and methods for use | Nocion Therapeutics, Inc. (US) | 2023-07-18 | — | — | US | disclosed |
| US-11643404-B2 | Ester substituted ion channel blockers and methods for use | Nocion Therapeutics, Inc. (US) | 2023-05-09 | — | — | US | disclosed |
| US-11643404-B2 | Ester substituted ion channel blockers and methods for use | Nocion Therapeutics, Inc. (US) | 2023-05-09 | — | — | US | disclosed |
| US-11377422-B2 | Charged ion channel blockers and methods for use | Nocion Therapeutics, Inc. (US) | 2022-07-05 | — | — | US | disclosed |
| WO-2021263205-A1 | COMBINATION THERAPY WITH DEOXYURIDINE TRIPHOSPHATASE INHIBITORS | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2021-12-30 | — | — | WO | disclosed |
| US-20210155634-A1 | NOVEL TRYPTOPHAN HYDROXYLASE INHIBITOR AND PHARMACEUTICAL COMPOSITION INCLUDING SAME | KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2021-05-27 | — | — | US | disclosed |
| US-8507522-B2 | Hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2013-08-13 | — | — | US | disclosed |
| US-20120149693-A1 | THERAPEUTIC COMPOUNDS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| US-20120076756-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2012-03-29 | — | — | US | disclosed |
| US-8101643-B2 | Benzimidazole derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-7985765-B2 | Therapeutic substituted pyrroles | ALLERGAN, INC. (US) | 2011-07-26 | — | — | US | disclosed |
| US-20100260715-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2010-10-14 | — | — | US | disclosed |
| US-20100233122-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2010-09-16 | — | — | US | disclosed |
| US-20100048664-A1 | THERAPEUTIC SUBSTITUTED PYRROLES | ALLERGAN, INC. (US) | 2010-02-25 | — | — | US | disclosed |
| WO-2010011626-A2 | PYRIDINYL MODULATORS OF ϒ-SECRETASE | JANSSEN PHARMACEUTICA NV (BE) | 2010-01-28 | — | — | WO | disclosed |
| US-20090215779-A1 | OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS | ASTRAZENECA AB (SE) | 2009-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149693-A1 | THERAPEUTIC COMPOUNDS | HTR2C, GRK2, GRK3 | KDM4E 4270/4885TSHR 1441/4885LMNA 3453/4885 |
| US-20120076756-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | EIF2AK2, ZC3HAV1, HAVCR2 | KDM4E 553/4885TSHR 4648/4885LMNA 3064/4885 |
| US-20100260715-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, SLC10A1, EIF2AK2 | KDM4E 1193/4885TSHR 4687/4885LMNA 2800/4885 |
| US-20100233122-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | EIF2AK2, ZC3HAV1, HAVCR2 | KDM4E 553/4885TSHR 4648/4885LMNA 3064/4885 |
| US-11377422-B2 | Charged ion channel blockers and methods for use | TRPV1, TRPV2, TRPV5 | KDM4E 2621/4885TSHR 4055/4885LMNA 2685/4885 |
| US-20230233560-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1B, SLC26A4 | KDM4E 2973/4885TSHR 1187/4885LMNA 3018/4885 |
| US-20210155634-A1 | NOVEL TRYPTOPHAN HYDROXYLASE INHIBITOR AND PHARMACEUTICAL COMPOSITION INCLUDING SAME | TPH1, TPH2, IDO1 | KDM4E 637/4885TSHR 3349/4885LMNA 4503/4885 |
| US-20240239828-A1 | MANNOSE 6-PHOSPHATE OR ASGPR RECEPTOR BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS | M6PR, ASGR1, IGF2R | KDM4E 3972/4885TSHR 560/4885LMNA 2973/4885 |
| US-11701370-B2 | Phosphonium ion channel blockers and methods for use | TRPV1, TRPV5, TRPA1 | KDM4E 3130/4885TSHR 4454/4885LMNA 3757/4885 |
| US-20090215779-A1 | OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS | DGAT2, GPR119, DGAT1 | KDM4E 3220/4885TSHR 1168/4885LMNA 3179/4885 |
| US-11643404-B2 | Ester substituted ion channel blockers and methods for use | TRPV1, TRPA1, TRPV2 | KDM4E 1801/4885TSHR 3755/4885LMNA 2730/4885 |
| US-20100048664-A1 | THERAPEUTIC SUBSTITUTED PYRROLES | GOT2, FARS2, THPO | KDM4E 2057/4885TSHR 3620/4885LMNA 4127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.